Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bladder cancer is a significant health concern with a need for novel therapeutic targets.
• MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
• The specific role of microRNA-96 (miR-96) in bladder cancer remains to be fully elucidated.

Purpose of the Study:

• To investigate the role of miR-96 in bladder cancer cell proliferation, invasion, and apoptosis.
• To identify the molecular mechanisms underlying miR-96's function in bladder cancer.
• To explore the potential of targeting miR-96 as a therapeutic strategy for bladder cancer.

Main Methods:

• Reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used to assess miR-96 and HERG1 expression.
• Transfection with miR-96 inhibitors was employed to modulate miR-96 levels in bladder cancer cell lines.
• MTT, flow cytometry, and Transwell assays were utilized to evaluate cell viability, apoptosis, and invasion.
• Dual-luciferase reporter assays were performed to confirm the direct targeting of HERG1 by miR-96.

Main Results:

• miR-96 was significantly upregulated in bladder cancer cell lines (T24 and 5637) compared to normal uroepithelial cells (SV-HUC-1).
• Inhibition of miR-96 suppressed bladder cancer cell proliferation and invasion, induced apoptosis, and caused G1 cell cycle arrest.
• The human ether-à-go-go-related (HERG1) potassium channel was also overexpressed in bladder cancer cells and its expression was inversely correlated with miR-96 inhibition.
• Dual-luciferase assays confirmed that miR-96 directly targets HERG1.

Conclusions:

• miR-96 inhibition demonstrates anticancer effects on bladder cancer cells by reducing proliferation and invasion and promoting apoptosis.
• HERG1 is identified as a direct and functional target of miR-96 in bladder cancer.
• These findings support miR-96 as a promising therapeutic target for bladder cancer treatment.